The amplification syndrome (MDS) is a group of heterogeneic cloned blood diseases, characterized by bone marrow dysfunction and a decrease in outer blood cells. The changes in blood pictograms among MDS patients can be significant. The following is a detailed description of the difference in blood pictograms between MDS patients:
MDS patients treated pre-blood pictograms
Red cell count and haemoglobin level:
MDS patients often show moderate to severe anaemia, and haemoglobin levels may be below normal (men <13.5g/dL and women <12.0g/dL).
Red cell forms may be abnormal, such as the occurrence of red cell sizes and irregular patterns.
White cell count:
The total number of white cells may be normal, decreasing or increasing.
White cell-form anomalies, such as Pelger-Huët malformations, may occur.
Slab count:
The number of slabs may decrease, leading to increased hemorrhage.
Blood slabs may be abnormal, such as increased size.
Bone marrow:
The bone marrow growth may be active, but there are often abnormally developed blood cells, such as ringed iron particles, small giant nuclear cells, etc.
The bone marrow biopsy may indicate abnormal bone marrow structures, such as increased fat cells and reduced blood areas.
After the MDS patient is treated, it changes.
The treatment of MDS includes support for treatment, immuno-modification treatment, demethylated drugs, blood growth factors and blood stem cell transplants. The following changes in blood elephants after different treatments:
Support for treatment:
Blood transfusions: Intensified blood transfusions may temporarily increase haemoglobin levels, but have limited impact on white cells and slab counts.
Hemogenic growth factors: e.g., erythrocyte-generation (EPO) and particle-centre irritation factors (G-CSF) may increase the number of erythrocytes and white cell counts, but have a small impact on the slab count.
Immuno-regulating treatment/demethylated drugs:
These treatments may improve bone marrow blood function, thus increasing the number of red cells, white cells and slabs.
The bone marrow may indicate an abnormal decrease in blood cell development, but the effects may vary from human to human.
Blood stem cell transplant:
Following successful transplantation, blood elephants may return to normal, including red cells, white cells and slab count.
The bone marrow may indicate normal blood-making structures and functions.
There’s a difference between blood elephants.
Red cell and blood protein:
Pre-treatment: haemoglobin levels may decrease significantly and patients may suffer from severe anaemia.
Post-treatment: haemoglobin levels may increase, especially after treatment with blood transfusions and/or blood growth factors.
White cell:
Pre-treatment: White cell count may be abnormal, accompanied by morphological changes.
Post-treatment: White cell count may be normal, especially after the use of particle-cell concentration irritant factors.
Blood plate:
Pre-treatment: The slab count may decrease and increase the risk of haemorrhage.
Post-treatment: The slab count may pick up, especially after blood stem cell transplants.
Bone marrow:
Pre-treatment: bone marrow amplification abnormality, accompanied by an abnormally developing blood cell.
Post-treatment: bone marrow may improve, development abnormal blood cells are reduced and blood function is restored.
Conclusions
The difference in the blood ratio between MDS patients depends on a number of factors, including the severity of the disease, the type of treatment and the individual response of the patient. Pre-treatment haematological conditions are usually manifested in anaemia, white cell and plate abnormalities, and loss of bone marrow blood function. The extent and duration of the improvement may have improved after treatment. Regular monitoring of blood elephants is essential for assessing the effectiveness of treatment and adjusting treatment programmes.
